It’s a divorce everyone has an opinion on.
Federal judges in Maryland, New Hampshire and Washington, DC, blocked the Trump administration from following through on threats to cut off funding to universities that engage in DEI efforts.
Dana-Farber’s bold split from the Brigham is a culmination of Boston oncology’s complicated history
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
Joseph FraiettaPietro GenoveseSwim Across America, the nonprofit funding innovative clinical trials and patient-centered programs for cancer, awarded $450,000 grants to two of its beneficiaries, Alliance for Cancer Gene Therapy and Dana-Farber Cancer Institute, to support the work of novel gene and base editing techniques used in advanced cancer research, including targeted therapies, immunotherapies, and cellular therapies.
Kimberly Stegmaier was named chair of Pediatric Oncology at Dana-Farber Cancer Institute and associate chief of the Division of Hematology/Oncology at Boston Children’s Hospital. Her appointment is effective April 1.
Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage 3 or 4 clear cell renal cell carcinoma generated a successful anti-cancer immune response after initiation of a personalized cancer vaccine.
Researchers at Dana-Farber Cancer Institute developed a method to detect inflammation in the body using positron emission tomography imaging. This innovative probe targets CD45, a marker abundantly expressed on all immune cells but absent from other cell types.
The American Society of Clinical Oncology elected Elizabeth A. Mittendorf to lead as its president beginning in June 2026. Mittendorf, a long-time ASCO member and volunteer, will take office as president-elect immediately following the ASCO Annual Business Meeting in Chicago on June 2.
